维多利祖马布
地址
免疫系统
抗体
单克隆抗体
固有层
结肠炎
细胞粘附
免疫学
溃疡性结肠炎
炎症
炎症性肠病
细胞
医学
癌症研究
生物
病理
内科学
疾病
上皮
整合素
受体
遗传学
作者
Lisa Lou Schulze,Emily Becker,Mark Dedden,Lijuan Liu,Chiara Van Passen,Mariam Mohamed Abdou,Tanja M. Müller,Maximilian Wiendl,Karen A.-M. Ullrich,Imke Atreya,Moritz Leppkes,Arif B. Ekici,Philipp Kirchner,Michael Stürzl,Dan Sexton,Deborah Palliser,Raja Atreya,Britta Siegmund,Markus F. Neurath,Sebastian Zundler
标识
DOI:10.1093/ecco-jcc/jjad088
摘要
Ontamalimab has unique and broader mechanisms of action compared to vedolizumab. However, this seems to be compensated for by redundant cell trafficking circuits and leads to similar preclinical efficacy of anti-α4β7 and anti-MAdCAM-1 treatment. These results will be important for the interpretation of pending phase III data.
科研通智能强力驱动
Strongly Powered by AbleSci AI